Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
Lindi Chen(Newcastle University), Deborah A. Tweddle(Newcastle University)
Cited by 89
Related Papers
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
|British Journal of Cancer|2014|42